Generation of human induced pluripotent stem cell lines from three patients affected by Catecholaminergic Polymorphic ventricular tachycardia (CPVT) carrying heterozygous mutations in RYR2 gene

Bastien Cimarosti(Centre National de la Recherche Scientifique), Nathalie Gaborit(Centre National de la Recherche Scientifique), Michel De Waard(Inserm), Robin Canac(Centre National de la Recherche Scientifique), Anne Gaignerie(Centre National de la Recherche Scientifique), Aurore Girardeau(Institut du Thorax), Michel Ronjat(Inserm), Hervé Le Marec(Centre National de la Recherche Scientifique), Guillaume Lamirault(Centre National de la Recherche Scientifique), Patricia Lemarchand(Centre National de la Recherche Scientifique), Aude Derevier(Centre National de la Recherche Scientifique), Stéphan De Waard(University of Bern), Virginie Forest(Centre National de la Recherche Scientifique), Jean‐Baptiste Gourraud(Centre Hospitalier Universitaire de Nantes)
Stem Cell Research
January 27, 2022
10.1016/j.scr.2022.102688
Cited by 1

Related Papers

HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies
|Heart Rhythm|2011|1.5k
Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death
|Nature|2003|961
HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA)
|EP Europace|2011|904
Long-Term Prognosis of Patients Diagnosed With Brugada Syndrome
|Circulation|2010|850
Cardiac conduction defects associate with mutations in SCN5A
|Nature Genetics|1999|638